泽璟制药：注射用ZG006开展关键性临床试验并完成首例受试者入组

Core Viewpoint - Zai Lab (688266) has received feedback from the National Medical Products Administration (NMPA) regarding the conditional approval for the clinical trial of its investigational product, ZG006 injection, indicating progress in its development for advanced small cell lung cancer patients [1] Group 1 - The NMPA's Center for Drug Evaluation (CDE) has agreed to allow ZG006 to proceed with critical clinical trials based on current safety and efficacy data [1] - ZG006 has been included in the CDE's list of breakthrough therapies, targeting patients with advanced small cell lung cancer who have previously undergone platinum-based chemotherapy and at least one other systemic treatment [1] - The company has successfully completed the enrollment of the first subject in the critical clinical trial for ZG006 [1]